| Identification | Back Directory | [Name]
Rev 2'-O-MOE-5MeU-5'-amidite | [CAS]
1345715-43-6 | [Synonyms]
MOE-5MeU-5’-amidite
Rev2'-O-MOE-5MeU-5'-amidite
Rev 2'-O-MOE-5MeU-5'-amidite
3’-O-DMTr-2’-O-(2-methoxyethyl)-5-methyluridine-5’-CED
3’-O-DMTr-2’-O-(2-methoxy ethyl)-5-methyluridine-5’-CED phosphoramidite
3'-O-(4,4’-Dimethoxytrityl)-2'-O-(2-methoxyethyl)-5-methyluridine-5’-CED phosphoramidite
Uridine, 3'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methyl-, 5'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite]
((2R,3R,4R,5R)-3-(Bis(4-methoxyphenyl)(phenyl)methoxy)-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl (2-cyanoethyl) diisopropylphosphoramidite | [Molecular Formula]
C43H55N4O10P | [MDL Number]
MFCD32690001 | [MOL File]
1345715-43-6.mol | [Molecular Weight]
818.89 |
| Hazard Information | Back Directory | [Uses]
Rev 2’-O-MOE-5MeU-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | [References]
[1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
|
|